NCT04326985View on ClinicalTrials.gov

RCT Mesenchymal Stem Cells Versus Hyaluronic Acid in OA Knee):

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

January 30, 2019

Study Completion Date

February 28, 2019

Conditions
Osteoarthritis, Knee
Interventions
BIOLOGICAL

Autologous Mesenchymal Stem Cells Treatment (MSCs)

The MSCs treatment group patients will receive an intra-articular injection of a mesenchymal stem cell (MSCs) suspension in the affected knee.

DRUG

Hyaluronic acid (HA)

The HA group patient will be given a single intra-articular injection of hyaluronic acid sodium salt, Synvisc-One (TRB Chemedica Ltd.)

Trial Locations (1)

Unknown

Department of Orthopaedics & Traumatology, Hong Kong

All Listed Sponsors
lead

Chinese University of Hong Kong

OTHER

NCT04326985 - RCT Mesenchymal Stem Cells Versus Hyaluronic Acid in OA Knee): | Biotech Hunter | Biotech Hunter